RANBAXY has said it is confident
in the quality of the products
supplied to Australia, and did not
expect any interruption to supply.
The move follows the US Food
and Drug Administration (FDA)
prohibiting Ranbaxy’s Toansa
facility in India from producing and
distributing active pharmaceutical
ingredients (APIs) for the US market.
Ranbaxy said that an internal
risk assessment was underway to
ensure that each Toansa API lot had
been satisfactorily conducted.
“We will act swiftly to inform
the Australian market should
any finding negatively affect local
supply.”The above article was sent to subscribers in Pharmacy Daily's issue from 04 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Feb 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.